The paragraph at page 32, line 4:

B1

Scheme III illustrates the synthesis of aryl-substituted statine analogs via Weinreb amide formation and reduction followed by addition of a chiral enolate to give a diastereoselective product in a ratio of 7:1 of the desired isomer. This scheme can be generalized to make a variety of derivatized statine valine dimers with varying C- and N-terminal groups by selection of different stating materials and intermediates. For example, the aryl statine derivative may be varied by selecting a different arylmethylene aminoacid as a starting material. All of the aryl amino acids used to form a derivatized aryl-statine were commercially available, and obtained from Synthetec, Inc. Monmouth Junction, New Jersey.

The paragraph at page 51, line 5:

B2

This test compound was prepared by coupling commercially available 2-carboxy-diphenylether with the peptide 3,5-difluoroPhe/Sta-Val-Ala-Glu-Phe [SEQ ID NO:1] according to the standard EDC coupling procedures. The VAEF [SEQ ID NO:2] peptide sequence was previously established to possess inhibitory binding capability at the active site of the enzyme.

The paragraph at page 51, line 23:

B3

The geminal dimethyl analog of 32 was prepared as in Example 31, but using the 3,3-demethylglutaric anhydride. This groups was coupled to the derivatized Sta-Val-Ala-Glu-Phe [SEQ ID NO:3] pentapeptide and assayed for binding affinity in the enzyme system.

The paragraph at page 52, line 4:

B4 Glutaric anhydride was treated with methanol to provide the mono methyl ester, which was treated with phosgene to produce the mono methyl ester with the opposite end being the acid chloride. The acid chloride was treated with piperidine to form the amide. The methyl ester was then hydrolyzed to the free acid and coupled with the derivatized Sta-Val-Ala-Glu-Phe [SEQ ID NO:3] pentapeptide.

The paragraph at page 57, line 18:

B5 4-methylcinnoline is oxidized to 4-carboxycinnoline and then coupled to the 3,5-difluoroPhe/Sta-Val-Ala-Glu-Phe [SEQ ID NO:1].

In the Claims:

Cancel claims 2-3, 7, 17-18, 21-22, 24-46, 48-49, 53, 63-64, and 67-68 amend claims 1, 15, 20, 47, and 60, and add new claims 70-75, as follows.

B6 1) (Twice amended) A compound of formula 1



Formula 1

wherein: